This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
by Zacks Equity Research
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
BAYRYNegative Net Change VRNAPositive Net Change RXRXNegative Net Change RLYBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
by Ahan Chakraborty
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
by Zacks Equity Research
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
RHHBYNegative Net Change BMYNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK's Specialty Medicines Unit on a Strong Footing: Here's Why
by Kinjel Shah
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
SNYNegative Net Change AZNNegative Net Change GSKNegative Net Change MRKNegative Net Change
biotechs
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck
by Zacks Equity Research
VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.
SNYNegative Net Change MRKNegative Net Change LLYNegative Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
by Zacks Equity Research
Cogent Biosciences stock jumps 23.4% after bezuclastinib hits primary and all key secondary endpoints in a phase III systemic mastocytosis study.
BAYRYNegative Net Change COGTNegative Net Change VRNAPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
by Zacks Equity Research
Mustang Bio surges 180% after its brain cancer therapy, MB-101, earns FDA Orphan Drug status for two rare brain tumor types.
BAYRYNegative Net Change MBIOPositive Net Change VRNAPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
by Zacks Equity Research
Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.
SNYNegative Net Change BIIBNegative Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
by Zacks Equity Research
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
by Sundeep Ganoria
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
by Ahan Chakraborty
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical oncology-screening pharmaceuticals
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
by Zacks Equity Research
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
REGNNegative Net Change VRTXNegative Net Change NTLANo Net Change CRSPPositive Net Change
biotechs
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
by Zacks Equity Research
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
BMYNegative Net Change MRKNegative Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
by Zacks Equity Research
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
AZNNegative Net Change BMYNegative Net Change MRKNegative Net Change SMMTPositive Net Change
biotechs medical pharmaceuticals
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
by Zacks Equity Research
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
RHHBYNegative Net Change BMYNegative Net Change NVOPositive Net Change PRTANegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
by Ahan Chakraborty
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
NVOPositive Net Change MRKNegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Semiconductor and Biotech Drive EMCOR's Bookings?
by Sraddha Singha
EMCOR hits record RPOs as CHIPS and IRA acts drive long-term demand across semiconductor and biotech markets.
ACMNegative Net Change KBRNegative Net Change EMENegative Net Change
biotechs construction semiconductor
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
by Zacks Equity Research
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
AZNNegative Net Change EXELPositive Net Change PBYINegative Net Change SPRONegative Net Change
biotechs
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
by Sundeep Ganoria
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
JAZZNegative Net Change AXSMNegative Net Change HRMYNegative Net Change
biotechs marijuana medical
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
by Zacks Equity Research
NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.
NVSNegative Net Change BAYRYNegative Net Change VRNAPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
by Zacks Equity Research
Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
by Zacks Equity Research
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
REGNNegative Net Change NVSNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
by Zacks Equity Research
Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.
GSKNegative Net Change PFENegative Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore
by Zacks Equity Research
EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.
ALKSNegative Net Change EXELPositive Net Change VRNAPositive Net Change KNSAPositive Net Change
biotechnology biotechs
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
by Sundeep Ganoria
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
MRKNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals